CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma-Reference-Cited by-同舟云学术

CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma

Published:2022-09-08 Issue:6 Volume:40 Page:1333-1341
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Xu Bo,Li Shaoqian,Kang Bo,Fan Shangzhi,He Zunbo,Zhou Jiecan^ORCID

Funder

Postgraduate Scientific Research Innovation Project of Hunan Province

National Natural Science Foundation of China

Natural Science Foundation of Hunan Province

Scientific research Fund of hunan provincial education department

Scientific Research Fund Project of Hunan Provinci al Health Commission

Central government funds for guiding local scientific and Technological Development

Hunan Province Clinical Medical Technology Innovation Guidance Project

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-022-01300-z.pdf

Reference38 articles.

1. Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin 68(2):116–132

2. American Cancer Society (2022) Types of Hodgkin lymphoma. https://www.cancer.org/cancer/hodgkin-lymphoma/about/what-is-hodgkin-disease.html. Accessed June 2022

3. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33

4. American Cancer Society (2022) Key Statistics for Hodgkin Lymphoma. https://www.cancer.org/cancer/hodgkin-lymphoma/about/key-statistics.html. Accessed June 2022

5. Mottok A, Steidl C (2018) Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood 131(15):1654–1665

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision targeting in oncology: The future of conjugated drugs;Biomedicine & Pharmacotherapy;2024-08

2. Non‐IL‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA‐4 therapy;International Journal of Cancer;2024-01-05